Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Matt Rourke / AP

Republican Rep. Doug Collins of Georgia does not like the pharmacy benefit management industry, and he and others in Congress are ready and willing to regulate those companies, which serve as middlemen in the drug supply chain. "There's several things that are going to be coming up," Collins told Axios Tuesday.

I truly believe the PBM industry is one of the most detrimental pieces of health care.

Looking ahead: Collins, who has been in touch with the new Energy and Commerce Chairman Greg Walden, said he will reintroduce and add items to his 2015 bill that would have required greater transparency of the rebates, fees and costs tied to pharmacy benefit managers. Republican Morgan Griffith of Virginia also has sponsored legislation that would prohibit pharmacy benefit managers and other companies that sell Medicare Part D plans from reducing pharmacy claims retroactively.

Collins said Congress is turning up the heat after the EpiPen pricing backlash brought more attention to how pharmacy benefit managers get their cut of rising drug prices. "A lot of people assumed the big drug companies were just jacking up prices and manipulating the system. But you have to look at this other issue of the PBMs. It was sort of a hidden issue because they want to stay hidden," said Collins, who has received campaign funds from community pharmacists.

Why this matters: It's not clear any proposed legislation would significantly alter the business models of pharmacy benefit managers, who say they are innocent. But the growing list of political critics is an inauspicious sign for the industry, which is dominated by CVS, Express Scripts and UnitedHealth Group's OptumRx.

Go deeper

Del Rio bridge camp empty following Haitian migrant surge

A boy bathes himself in a jug of water inside a migrant camp at the U.S.-Mexico border on Sept. 21 in Del Rio, Texas. Photo: John Moore/Getty Images

The last migrants camping under the Del Rio International Bridge, which connects Texas and Mexico, departed on Friday, Homeland Security Secretary Alejandro Mayorkas announced during a White House press briefing.

Driving the news: Thousands of migrants, mostly from Haiti, had arrived to the makeshift camp after crossing the southern border seeking asylum. Roughly 1,800 migrants will now head to U.S. Customs and Border Protection processing centers.

White House says it expects federal contractors to be vaccinated by Dec. 8

Photo: Stefani Reynolds/Bloomberg via Getty Images

The White House said in new guidance Friday that it expects millions of federal contractors to be vaccinated against the coronavirus no later than Dec. 8.

Why it matters: Companies with federal contractors have been waiting for formal guidance from the White House before requiring those employees to get vaccinated, according to Reuters.

CDC director maintains Pfizer booster recommendation for high-risk workers

Rochelle Walensky listens during a confirmation hearing on July 20. Photo: Stefani Reynolds/The New York Times/Bloomberg via Getty Images

Centers for Disease Control and Prevention director Rochelle Walensky on Friday reiterated her decision to go against a recommendation by a CDC advisory panel that refused to endorse booster shots for workers whose jobs put them at high risk for contracting COVID-19.

Driving the news: "Our healthcare systems are once again at maximum capacity in parts of the country, our teachers are facing uncertainty as they walk into the classroom," Walensky said at a Friday briefing. "I must do what I can to preserve the health across our nation."